|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/32 | (2013.01) |
| C07K 16/32 | (2006.01) | ||
| A61K 31/4745 | (2006.01) | ||
| A61K2039/505 | (2013.01) | ||
| A61K 31/522 | (2006.01) | ||
| C07K2317/24 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| C07K2317/732 | (2013.01) | ||
| A61P 35/02 | (2006.01) | ||
| A61K 47/6889 | (2017.08) | ||
| A61K 47/6849 | (2017.08) | ||
| A61K 47/6851 | (2017.08) | ||
| A61K 47/6855 | (2017.08) | ||
| A61K 47/6857 | (2017.08) | ||
| A61K 47/6863 | (2017.08) | ||
| A61K 47/6871 | (2017.08) | ||
| A61K 47/6803 | (2017.08) | ||
| A61P 1/04 | (2018.01) | ||
| A61P 1/18 | (2018.01) | ||
| A61P 11/00 | (2018.01) | ||
| A61P 13/08 | (2018.01) | ||
| A61P 13/10 | (2018.01) | ||
| A61P 13/12 | (2018.01) | ||
| A61P 15/00 | (2018.01) | ||
| A61P 17/00 | (2018.01) | ||
| A61P 19/08 | (2018.01) | ||
| A61P 25/00 | (2018.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 35/02 | (2018.01) | ||
| A61P 37/02 | (2018.01) | ||
| A61P 43/00 | (2018.01) |
| (11) | Number of the document | 3092256 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15734849.1 |
| Date of filing the European patent application | 2015-01-08 | |
| (97) | Date of publication of the European application | 2016-11-16 |
| (45) | Date of publication and mention of the grant of the patent | 2022-05-18 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/CN2015/070379 |
| Date | 2015-01-08 |
| (87) | Number | WO 2015/103989 |
| Date | 2015-07-16 |
| (30) | Number | Date | Country code |
| 201410011324 | 2014-01-10 | CN | |
| 201410011262 | 2014-01-10 | CN | |
| 201410011362 | 2014-01-10 | CN |
| (72) |
LI, Lixin , CN
|
| (73) |
Birdie Biopharmaceuticals Inc. ,
Sertus Chambers
P.O. Box 2547
Cassia Court
Camana Bay, Grand Cayman,
KY
|
| (54) | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY |
| COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY |